Presentation is loading. Please wait.

Presentation is loading. Please wait.

BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden

Published byAdele Robertson Modified over 6 years ago

Similar presentations

Presentation on theme: "BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden"— Presentation transcript:

1 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) Beads & Nucleated Cells – HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

2 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) Beads & Nucleated Cells (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

3 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) Nucleated Cells  HLA-ABC+ (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

4 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) Nucleated Cells  HLA-ABC+ (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

5 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) PI- Live Cells (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

6 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) PI- Live Cells (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

7 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) HLA-ABC+ (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

8 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) HLA-ABC+ (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

9 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) HLA-ABC+ (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

10 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) HLA-ABC+ (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

11 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) HLA-ABC+  Annexin V vs PI (HLA-ABC Staining) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

12 BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden
(5/27/16 – Day 13 of Drug Treatment) HLA-ABC+  Annexin V vs PI (Isotype Control) PB SPL BM 5175 (20mg/kg I-BET) 5176 (20mg/kg I-BET) 5154 (Vehicle) 5171 (Vehicle)

Download ppt "BET-EFF (MV-4-11): Sacrificing 4 Sick Mice – Tumor Burden"

Similar presentations

Supplementary Figure S1.

Supplementary Figure S1.
Fig. 2. The expression of pKr-2 in the substantia nigra (SN) of patients with Parkinson's disease (PD). (A, B) Western blot analysis for pKr-1-2 and pKr-2,

Fig. 2. The expression of pKr-2 in the substantia nigra (SN) of patients with Parkinson's disease (PD). (A, B) Western blot analysis for pKr-1-2 and pKr-2,
BET-EFF (MV-4-11): Sacrificing 2 Sick Mice – Tumor Burden

BET-EFF (MV-4-11): Sacrificing 2 Sick Mice – Tumor Burden
Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.
BM SPL PB Beads & Nucleated HLA-ABC+ Beads & Nucleated HLA-ABC+

BM SPL PB Beads & Nucleated HLA-ABC+ Beads & Nucleated HLA-ABC+
Drug concentration (μM)

Drug concentration (μM)
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes
Volume 21, Issue 12, Pages (December 2017)

Volume 21, Issue 12, Pages (December 2017)
Median Tumor Development Time

Median Tumor Development Time
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy by Marta Chesi, Geoffrey M. Matthews, Victoria.

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy by Marta Chesi, Geoffrey M. Matthews, Victoria.
A B A B C Supplementary Fig. 8 Supplementary Fig. 9

A B A B C Supplementary Fig. 8 Supplementary Fig. 9
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Effects of senescent cells on activity.

Effects of senescent cells on activity.
A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.

A B C D E F Supplementary Fig. 1. Gating strategy for CD44+CD133+CD24+ B16 tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells.
A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.

A B C D E F Supplementary Fig. 2. Gating strategy for CD44+CD24+ ID8agg tumor initiating cells (TIC). Cells were gated on CD44. CD44 positive cells were.
Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
BV6 increases tumor burden in bone.

BV6 increases tumor burden in bone.
Figure 2S (Supplementary Data)

Figure 2S (Supplementary Data)

Similar presentations

Ads by Google